Skip to main content
PTHS
NYSE Life Sciences

Pelthos Q3: Zelsuvmi Revenue Up 114% to $15.2M, Net Loss Narrows to $7.9M

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Positive
Importance info
7
Price
$9.39
Mkt Cap
$36.92M
52W Low
$8.72
52W High
$37.4
52W Position info
7.7% above low
Off High info
75% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

PTHS is trading near its 52-week low of $8.72 (7.7% above the low).

Summary

Pelthos reported Q3 2026 Zelsuvmi revenue of $15.2 million, up 114% year over year, and cut its net loss to $7.9 million. Cash of $17.7 million plus a new $10.0 million draw funds the plan while the Castle Creek merger targets a Q1 2027 close.


Key Events · Earnings and Guidance · PTHS

  • Zelsuvmi Revenue Doubles Year Over Year

    Q3 2026 net product revenue was $15.2 million versus $7.1 million a year earlier, a 114% increase, on 12,384 units dispensed, up 4% sequentially.

  • Net Loss Narrows Sharply

    Net loss fell to $(7.9) million from $(23.4) million in Q2 2026, and Adjusted EBITDA improved to $(5.6) million from $(10.4) million a year ago.

  • Horizon Facility Upsized and Drawn

    An amended Horizon loan provides up to $50.0 million; the company drew $10.0 million on October 30, 2026, bringing borrowings to $40.0 million, with $10.0 million more available before December 31, 2027 subject to trailing twelve-month net revenue of at least $70.0 million.

  • Cash Runway Tied to Growth

    Cash was $17.7 million at September 30, 2026, before the $10.0 million October draw; the company says this plus current commercial projections supports its business plan.


Analysis · PTHS · Life Sciences

Zelsuvmi revenue more than doubled year over year to $15.2 million, and the quarterly net loss narrowed sharply to $7.9 million from $23.4 million in Q2, helped by a $4.1 million non-cash gain on convertible-debt remeasurement and lower SG&A. The real constraint is cash: $17.7 million on hand at September 30 plus a $10.0 million draw on October 30 under an upsized $50.0 million Horizon facility, leaving $40.0 million outstanding and only $10.0 million more available before December 31, 2027, and only if trailing twelve-month net revenue reaches $70.0 million. Against roughly $5.6 million of quarterly cash burn, that runway depends on continued Zelsuvmi growth and the pending Castle Creek merger closing by the end of Q1 2027.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PTHS was trading at $9.39 on NYSE in the Life Sciences sector, with a market capitalization of approximately $36.9M. The 52-week trading range was $8.72 to $37.40. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PTHS - Latest Insights

PTHS
Nov 03, 2026, 8:20 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $10.78
Real-time Price: $9.39 info
Change: -$1.39 (-13%) info
Market Cap: $36.92M info
PTHS
Oct 30, 2026, 9:20 AM EDT
Filing Type: 425
Importance Score:
9
Price at Filing: $19.86
Real-time Price: $9.39 info
Change: -$10.47 (-53%) info
Market Cap: $36.92M info
PTHS
Oct 30, 2026, 9:17 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $20.00
Real-time Price: $9.39 info
Change: -$10.61 (-53%) info
Market Cap: $36.92M info